CGRP monoclonal antibodies reduced headache days from 30 to 9.5 per month in medication overuse headache patients without requiring abrupt drug discontinuation or hospitalization.
30→9.5 daysmonthly headache days after three CGRP antibody injections
What the researchers found
After three CGRP-mAb injections, monthly headache days decreased from median 30.0 to 9.5, with 75% of patients achieving ≥50% reduction in headache frequency without abrupt medication discontinuation.
Why it matters
Medication overuse headache affects millions of migraine patients, and the standard treatment of abrupt drug withdrawal is notoriously difficult to maintain. This approach offers a gentler alternative that may improve compliance and patient quality of life.
The numbers in context
Data collected at baseline and 1 month after each injection. Multiple outcome measures tracked.
How the study worked
Real-world prospective cohort study of 33 migraine patients with medication overuse headache, measuring outcomes at baseline and after each of three monthly CGRP monoclonal antibody injections.
Who was studied
Migraine patients with medication overuse headache
What this study cannot tell us
Small sample size (33 patients); no control group or comparison with standard abrupt withdrawal; single-center study in Japan; short follow-up of three months; open-label design introduces potential placebo effects.
How to read the evidence
Moderate evidence from a small real-world cohort study without controls. The dramatic effect size is encouraging but requires confirmation in larger, controlled trials.
When this study was published
Published in 2024, reflecting current clinical practice with CGRP monoclonal antibodies.
The bigger picture
CGRP antibodies are transforming migraine treatment, and this study suggests they may also offer a more humane approach to breaking the medication overuse cycle, potentially replacing the painful cold-turkey withdrawal that many patients dread or fail to complete.
Questions still open
- How do outcomes compare directly to the standard abrupt discontinuation approach in a randomized trial?
- Do the benefits persist after CGRP antibody treatment is stopped?
- Which CGRP antibody (galcanezumab, fremanezumab, erenumab) works best for medication overuse headache specifically?
Common questions
Do you have to stop all your headache medications at once when using CGRP antibodies for medication overuse headache?
How quickly do CGRP antibodies help with medication overuse headache?
Read the original research
Real-world clinical results of CGRP monoclonal antibody treatment for medication overuse headache of migraine without abrupt drug discontinuation and no hospitalization.
Heliyon, 10(22), e40190
Citation
Tanei, Takafumi; Fuse, Yutaro; Maesawa, Satoshi; Nishimura, Yusuke; Ishizaki, Tomotaka; Nagashima, Yoshitaka; Mutoh, Manabu; Ito, Yoshiki; Hashida, Miki; Suzuki, Takahiro; Yamamoto, Syun; Wakabayashi, Toshihiko; Saito, Ryuta. (2024). Real-world clinical results of CGRP monoclonal antibody treatment for medication overuse headache of migraine without abrupt drug discontinuation and no hospitalization.. Heliyon, 10(22), e40190. https://doi.org/10.1016/j.heliyon.2024.e40190